Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PALLADONE vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agonist at mu-opioid receptors, modulating pain perception via central and peripheral pathways.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Management of moderate to severe pain requiring daily opioid treatment
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Immediate-release: 4-8 mg orally every 4-6 hours as needed for pain; extended-release: 8 mg orally every 12 hours, titrated based on response and tolerance.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life is approximately 18 hours (range 12-24 h); supports extended dosing intervals.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Hepatic via CYP3A4 and CYP2D6 to active metabolite hydromorphone; also via glucuronidation.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily renal (90%) as unchanged drug and glucuronide conjugate; ~10% biliary/fecal.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 95-99% bound to albumin and alpha-1-acid glycoprotein.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Vd ~4 L/kg (range 2-6 L/kg). Large Vd indicates extensive tissue distribution.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: ~40% (range 20-60%) due to first-pass metabolism; rectal: similar to oral.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
For Cr Cl 30-59 m L/min: start with 50% of recommended dose and titrate cautiously; for Cr Cl <30 m L/min: not recommended.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: start at 50% of usual dose and monitor; Child-Pugh Class C: not recommended.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Weight-based dosing: 0.1-0.2 mg/kg orally every 4-6 hours as needed (immediate-release); maximum single dose 5 mg. Extended-release not recommended in children.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Start at the low end of dosing range (e.g., 2-4 mg immediate-release every 4-6 hours) and titrate slowly; monitor for increased sensitivity and respiratory depression.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; interaction with alcohol and CNS depressants.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Respiratory depression,Addiction and abuse potential,Risks from concomitant use of benzodiazepines or other CNS depressants,Neonatal opioid withdrawal syndrome,Adrenal insufficiency,Severe hypotension,Seizures,Serotonin syndrome with serotonergic drugs
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Significant respiratory depression,Acute or severe bronchial asthma,Known or suspected gastrointestinal obstruction,Hypersensitivity to hydromorphone or any component,Concurrent use of MAOIs or within 14 days
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid grapefruit juice as it may increase hydromorphone levels. Avoid alcohol in any form (including beverages, cooking wines, and medications containing alcohol) due to risk of additive CNS depression and respiratory depression. High-fat meals may delay absorption; take consistently with or without food to maintain stable effects.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
PALLADONE (hydromorphone) is an opioid agonist. Data in pregnancy are limited. First trimester: Use is associated with a small risk of congenital malformations, particularly neural tube defects, based on some epidemiologic studies; however, absolute risk is low. Second and third trimesters: Chronic use may lead to fetal dependence and neonatal opioid withdrawal syndrome (NOWS) after delivery. Additionally, use near term may cause neonatal respiratory depression, and use during labor may prolong labor.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Hydromorphone is excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 0.65. The estimated infant dose via breast milk is about 0.5-1% of the maternal weight-adjusted dose. While generally considered compatible with breastfeeding at low maternal doses, caution is advised; monitor infant for excessive drowsiness, respiratory depression, and feeding difficulties. Avoid use in mothers with high-dose or prolonged therapy.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Pregnancy may alter pharmacokinetics of hydromorphone: increased clearance and volume of distribution may reduce serum concentrations. Dose adjustments may be necessary to maintain analgesic efficacy. Close monitoring for breakthrough pain and signs of withdrawal is recommended. Due to lack of robust data, titrate dose based on clinical response and maternal safety, using the lowest effective dose. Avoid abrupt discontinuation to prevent withdrawal.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
PALLADONE (hydromorphone extended-release) is a potent mu-opioid agonist. Do not crush or allow patients to chew capsules; this can cause rapid release and fatal overdose. Use with extreme caution in patients with respiratory compromise, COPD, or sleep apnea. Initiate at the lowest effective dose and titrate slowly. Monitor for constipation and prescribe a bowel regimen prophylactically. Consider naloxone co-prescription for high-risk patients. Avoid use in patients with paralytic ileus or suspected GI obstruction. Renal impairment requires dose adjustment due to accumulation of hydromorphone-3-glucuronide.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Swallow capsules whole; do not crush, chew, or dissolve them as this can cause a fatal overdose.,Avoid alcohol and any medications containing alcohol while taking this drug as it increases risk of dangerous side effects.,Do not drive or operate heavy machinery until you know how PALLADONE affects you; it may cause dizziness or drowsiness.,This medication carries a risk of addiction, abuse, and misuse; store it securely out of reach of others.,Report any difficulty breathing, extreme drowsiness, confusion, or signs of allergic reaction immediately.,Do not stop suddenly; your doctor will help you taper off to prevent withdrawal symptoms.,Constipation is common; increase fluid and fiber intake and use laxatives as recommended by your doctor.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PALLADONE vs ABSTRAL, answered by our medical review team.
PALLADONE is a Opioid Analgesic that works by Agonist at mu-opioid receptors, modulating pain perception via central and peripheral pathways.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PALLADONE and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PALLADONE is: Immediate-release: 4-8 mg orally every 4-6 hours as needed for pain; extended-release: 8 mg orally every 12 hours, titrated based on response and tolerance.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PALLADONE and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PALLADONE is classified as Category C. PALLADONE (hydromorphone) is an opioid agonist. Data in pregnancy are limited. First trimester: Use is associated with a small risk of congenital malformations, particularly neural. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.